Correlation Between Molecular Partners and Apellis Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Molecular Partners and Apellis Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and Apellis Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Molecular Partners AG and Apellis Pharmaceuticals, you can compare the effects of market volatilities on Molecular Partners and Apellis Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of Apellis Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and Apellis Pharmaceuticals.

Diversification Opportunities for Molecular Partners and Apellis Pharmaceuticals

0.15

Correlation Coefficient

Molecular Partners  Apellis Pharmaceuticals

Average diversification

The 3 months correlation between Molecular and Apellis is 0.15. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and Apellis Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apellis Pharmaceuticals and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with Apellis Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apellis Pharmaceuticals has no effect on the direction of Molecular Partners i.e., Molecular Partners and Apellis Pharmaceuticals go up and down completely randomly.

Pair Corralation between Molecular Partners and Apellis Pharmaceuticals

Given the investment horizon of 90 days Molecular Partners AG is expected to generate 2.01 times more return on investment than Apellis Pharmaceuticals. However, Molecular Partners is 2.01 times more volatile than Apellis Pharmaceuticals. It trades about 0.04 of its potential returns per unit of risk. Apellis Pharmaceuticals is currently generating about -0.04 per unit of risk. If you would invest  564.00  in Molecular Partners AG on August 31, 2024 and sell it today you would earn a total of  19.00  from holding Molecular Partners AG or generate 3.37% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Molecular Partners AG  vs.  Apellis Pharmaceuticals

Molecular Partners

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain essential indicators, Molecular Partners displayed solid returns over the last few months and may actually be approaching a breakup point.

Apellis Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Apellis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's essential indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Pair Trading with Molecular Partners and Apellis Pharmaceuticals

The main advantage of trading using opposite Molecular Partners and Apellis Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, Apellis Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will offset losses from the drop in Apellis Pharmaceuticals' long position.

The idea behind Molecular Partners AG and Apellis Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.